Angiogenesis and lung cancer: prognostic and therapeutic implications.
about
Anti-angiogenic therapy for lung cancerEndothelial podosome rosettes regulate vascular branching in tumour angiogenesis.A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC).Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen.The -271 G>A polymorphism of kinase insert domain-containing receptor gene regulates its transcription level in patients with non-small cell lung cancer.Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer.Estradiol and nicotine exposure enhances A549 bronchioloalveolar carcinoma xenograft growth in mice through the stimulation of angiogenesisCirculating endothelial-derived activated microparticle: a useful biomarker for predicting one-year mortality in patients with advanced non-small cell lung cancerVeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab.Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).Human papillomavirus up-regulates MMP-2 and MMP-9 expression and activity by inducing interleukin-8 in lung adenocarcinomas.Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.Anti-angiogenic agents in the treatment of non-small cell lung cancer.Aryl hydrocarbon receptor-induced adrenomedullin mediates cigarette smoke carcinogenicity in humans and mice.Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo.Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.Perceived health in lung cancer patients: the role of positive and negative affect.Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer.Activating transcription factor 3 is overexpressed in human glioma and its knockdown in glioblastoma cells causes growth inhibition both in vitro and in vivo.URG4/URGCP enhances the angiogenic capacity of human hepatocellular carcinoma cells in vitro via activation of the NF-κB signaling pathway.An oligonucleotide microarray for high-throughput sequencing of the mitochondrial genomeSingle nucleotide polymorphisms of MAGE-A3 gene and its clinical implications in Chinese patients with non-small cell lung cancer (NSCLC)Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.EGFR inhibitors: what have we learned from the treatment of lung cancer?Biomarkers and the genetics of early neoplastic lesions.VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib.Anti-vascular endothelial growth factor therapies at the crossroads: linifanib for non-small cell lung cancer.Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy.Bevacizumab in the treatment of non-small-cell lung cancer.A human IgG-like bispecific antibody co-targeting epidermal growth factor receptor and the vascular endothelial growth factor receptor 2 for enhanced antitumor activityPerfusion parameters as potential imaging biomarkers for the early prediction of radiotherapy response in a rat tumor model.Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours.Combined anti-proliferative and anti-angiogenic strategies for cancer.Levels of circulating microparticles in lung cancer patients and possible prognostic value.Bombesin induces angiogenesis and neuroblastoma growth.Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab.Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancerCombination of radiotherapy and targeted therapies in the treatment of locally advanced non-small cell lung cancer.Bevacizumab: overview of the literature.Vandetanib for the treatment of lung cancer.
P2860
Q24240857-49B7607E-8C44-419F-94F2-B9933DB26CF4Q30664059-2841D7A7-DF3D-410F-A8DE-99AEFC1314D7Q33415143-97986274-8185-4D28-9852-98333ACBBAA4Q33436643-E68C7942-1648-4D30-BA10-A4DB9958A1D0Q33444299-F17194AB-6D0F-48D1-84CA-A14301DFEEE5Q33817062-D50E1CC9-0C89-468E-98F1-F9496D9B9521Q33836078-EB017511-FA94-4675-B93E-53382DE3BF9FQ33908558-23B07680-F16C-4764-B4B5-0373D02C0989Q33937644-CC7B3848-07BA-4C4F-A120-294F07637433Q34026037-9D0FF098-4938-4BF6-9D0C-D35A4CAD5692Q34563083-677C7988-4E96-4C8D-9BCC-B32579BD51FFQ34578277-F88CCAED-D2B7-477C-A4D0-DE0B806C9769Q34821321-A0604682-D8E5-4447-89E8-C5704D750FA2Q35120292-88D31774-0100-49AD-90A7-69376020D4C7Q35152542-86DB8FE8-8CD9-43C5-8B61-A9D348069E11Q35346619-872E3B76-1408-4D46-93F6-32BF4A54BFE3Q35386158-26103974-4BC3-4D38-BA3D-959629CF9FA4Q35584074-185DB231-1EC1-4A98-A2DA-261D3CA66103Q35609946-C44038A7-BCCE-449E-9953-D0891C9C2443Q35623604-5CE4E6F5-421D-4813-9606-D6C3320B0DDEQ35790280-98C65F7C-AD45-4FCD-A993-D46E57EDAC8DQ35812837-3A68C57F-AC38-45FE-A81C-D7A5518CAC96Q35832330-EB375AF9-4880-472E-A83B-60436F8DEF67Q36306259-495A7B5C-36FF-439D-8DB0-5D8009F09ECAQ36340108-D799F001-C52D-4B85-AC5D-5859D26D4BD8Q36419366-3697A330-AAFF-49D3-A39D-D52AD709BCE0Q36594240-7EF5CB2F-80DB-41A9-ADFF-C91943AB87C1Q36691776-84B476BB-2776-41D0-9F94-3D53E8F76CF0Q36832129-995EEDAA-4E1D-43FE-99D9-7DDF053B02C6Q36844361-398E3691-863D-42AE-B397-7BDA18B53310Q36878999-285A1839-33D2-4ECE-9252-FD9ED4F6A857Q36965055-691F0E58-AD4B-4C96-B479-524D0F9D7E01Q37111832-F1AC0240-184F-4255-835C-BC22EF762C33Q37208677-CFE7D372-A027-4B81-8082-11F113A0FFFDQ37259715-DD978343-5883-4E45-BF3A-24CF13F77810Q37290520-43F9CEBD-2FF1-42AD-8537-78DE4506D36EQ37670436-18A630A3-DFD5-4D20-9244-204E6ADDFAABQ37853481-40424E88-9091-4645-A420-60D4ACF6FCCFQ38010797-20FAD1B7-D37E-4FF3-9150-245B8E5C8D22Q38016190-81A315F6-4E7E-4ACF-AAF0-A9DC40384700
P2860
Angiogenesis and lung cancer: prognostic and therapeutic implications.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Angiogenesis and lung cancer: prognostic and therapeutic implications.
@ast
Angiogenesis and lung cancer: prognostic and therapeutic implications.
@en
Angiogenesis and lung cancer: prognostic and therapeutic implications.
@nl
type
label
Angiogenesis and lung cancer: prognostic and therapeutic implications.
@ast
Angiogenesis and lung cancer: prognostic and therapeutic implications.
@en
Angiogenesis and lung cancer: prognostic and therapeutic implications.
@nl
prefLabel
Angiogenesis and lung cancer: prognostic and therapeutic implications.
@ast
Angiogenesis and lung cancer: prognostic and therapeutic implications.
@en
Angiogenesis and lung cancer: prognostic and therapeutic implications.
@nl
P356
P1476
Angiogenesis and lung cancer: prognostic and therapeutic implications.
@en
P2093
Alan Sandler
P304
P356
10.1200/JCO.2005.18.853
P407
P577
2005-05-01T00:00:00Z